XTAI
4155
Market cap64mUSD
Oct 06, Last price
14.20TWD
1D
-3.73%
1Q
-9.55%
Jan 2017
-42.72%
IPO
-22.36%
Name
OK Biotech Co Ltd
Chart & performance
P/E
24.92
P/S
1.32
EPS
0.57
Div yield, %
2.11%
Shrs. gr., 5y
10.57%
Rev. gr., 5y
0.95%
Revenues
1.56b
-6.81%
Net income
82m
-12.26%
CFO
320m
+384.91%
Dividend
Oct 20, 20260.3 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
OK Biotech Co., Ltd., established in 2006 and based in Hsinchu City, Taiwan, is a global producer and vendor of blood glucose meters. Its product line further encompasses nebulizers, glucometers, blood sugar meters, blood glucose test strips, and personal sound amplifiers.
Key people
Youci Liu
Vice Chairman of the Board · since 2022
Chia To Lai
Chairman of the Board, General Manager · since 2017
Siou-Cin Wang
Deputy General Manager-Business Division · since 2009
Qingbiao Chen
Director · since 2024
Qizheng Hou
Assistant General Manager of Finance & Accounting Division, Director · since 2024
Director · since 2024
Zhengang Wang
Director · since 2024
Director · since 2024
Guquan Chen
Independent Director · since 2021
Lifen He
Independent Director · since 2021
Shiyi Lin
Independent Director · since 2018
Jingjun Lu
Independent Director · since 2023
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||